Motilal Oswal is bullish on Aurobindo Pharma has recommended buy rating on the stock with a target price of Rs 1050 in its research report dated February 10, 2017.
Motilal Oswal's research report on Aurobindo Pharma
ARBP trades at 14x FY18E EPS, at >25% discount to peers. The valuation gap is expected to narrow on account of the company’s increasing profitability, strong earnings growth trajectory (19% CAGR till FY19E), and improving free cash flow. ARBP remains one of our top picks in the sector, with a target price of INR 1,050 (20x 1HFY19E EPS).
For all recommendations, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.